6/4
08:04 am
alks
Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
6/3
07:10 am
alks
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024 [Yahoo! Finance]
Low
Report
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024 [Yahoo! Finance]
6/3
07:00 am
alks
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
Low
Report
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
6/3
07:00 am
alks
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
Low
Report
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
5/31
01:19 pm
alks
Why Is Alkermes (ALKS) Down 2.7% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Alkermes (ALKS) Down 2.7% Since Last Earnings Report? [Yahoo! Finance]
5/29
04:00 pm
alks
Alkermes to Participate in Two Upcoming Investor Conferences
Low
Report
Alkermes to Participate in Two Upcoming Investor Conferences
5/29
04:00 pm
alks
Alkermes to Participate in Two Upcoming Investor Conferences
Low
Report
Alkermes to Participate in Two Upcoming Investor Conferences
5/28
07:20 am
alks
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 [Yahoo! Finance]
Low
Report
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 [Yahoo! Finance]
5/28
07:00 am
alks
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
Low
Report
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
5/28
07:00 am
alks
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
Low
Report
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
5/23
11:50 am
alks
Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Cantor Fitzgerald from $43.00 to $48.00. They now have an "overweight" rating on the stock.
Low
Report
Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Cantor Fitzgerald from $43.00 to $48.00. They now have an "overweight" rating on the stock.
5/14
07:00 am
alks
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
Low
Report
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
5/14
07:00 am
alks
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
Low
Report
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
5/3
11:32 pm
alks
Alkermes plc (NASDAQ: ALKS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Alkermes plc (NASDAQ: ALKS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
5/2
02:07 pm
alks
Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
5/2
01:42 pm
alks
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
Low
Report
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
5/2
07:00 am
alks
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Low
Report
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
5/2
07:00 am
alks
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Low
Report
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
5/1
11:25 am
alks
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Low
Report
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
5/1
07:12 am
alks
Alkermes plc Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
Alkermes plc Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/1
07:00 am
alks
Alkermes plc Reports First Quarter 2024 Financial Results
Low
Report
Alkermes plc Reports First Quarter 2024 Financial Results
5/1
07:00 am
alks
Alkermes plc Reports First Quarter 2024 Financial Results
Low
Report
Alkermes plc Reports First Quarter 2024 Financial Results
4/24
07:10 am
alks
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 [Yahoo! Finance]
Low
Report
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 [Yahoo! Finance]
4/24
07:00 am
alks
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Low
Report
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
4/24
07:00 am
alks
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Low
Report
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1